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The proportions both of elderly patients in the world and of elderly patients with cancer are both increasing. In the evaluation of
these patients, physiologic age, and not chronologic age, should be carefully considered in the decision-making process prior to
both cancer screening and cancer treatment in an eﬀort to avoid ageism. Many tools exist to help the practitioner determine the
physiologic age of the patient, which allows for more appropriate and more individualized risk stratiﬁcation, both in the pre- and
postoperativeperiodsaspatientsareevaluatedforsurgicaltreatmentsandmonitoredforsurgicalcomplications,respectively.Dur-
ing and after operations in the oncogeriatric populations, physiologic changes occuring that accompany aging include impaired
stress response, increased senescence, and decreased immunity, all three of which impact the risk/beneﬁt ratio associated with can-
cer surgery in the elderly.
1.Introduction
Due in large part to a steadily rising life expectancy in the
most privileged parts of the world, currently greater than
80 years in much of Europe, North America, Australia, and
New Zealand [1], cancer is an increasingly common lifetime
event, occurring approximately 10-fold more frequently in
the elderly than in younger patients [2–4]. The deﬁnition of
“elderly” is rather elusive and less meaningful as physiologic
age becomes recognized as more relevant than chronological
age. Nevertheless, studies must use a cut-oﬀ value, such as 65
years [2, 3]a n d8 5y e a r s[ 4], to deﬁne the older population
at higher risk of developing cancer. For those who survive to
old age, the lifetime risk of developing any invasive cancer is
higher for men (44%) than women (38%) [4].
Despite the growing emphasis on physiologic age versus
chronologic age in the assessment of an individual’s risk/
beneﬁt ratio when faced with the prospect of cancer surgery,
there are several issues relevant to the elderly population (as
identiﬁed by chronological age) as they face increasing rates
of cancer. These issues include but are not limited to the
underrepresentation of elderly patients in randomized clini-
caltrials[5–7],theimpactofsocialconnectionsonriskinthe
elderly [8, 9], and the changing risk/beneﬁt ratio associated
with cancer screening, ageism among professional health
providers, the possibility of increased risk of perioperative
morbidity and mortality following cancer surgery, and the
characterized physiologic changes associated with aging and
impactingtheabilityofoncogeriatricpatientstoavoidcancer
and to recover from cancer surgery.
In the present paper, we will ﬁrst discuss several salient
points speciﬁc to the surgical care of the elderly patient, in-
cludingfundamentalconsiderationoftheconceptofchrono-
logic versus physiologic age and how to best assess it, then
moving to the presurgical issue of cancer screening in the
elderly, then, once a diagnosis of cancer is established, to the
issue of ageism in the decision-making process regarding
cancer surgery in the elderly, and ﬁnally, once an operation is
undertaken, some outcomes following cancer operations in
the elderly and some age-speciﬁc mechanisms of immunity
and carcinogenesis relevant to the oncogeriatric popula-
tion.2 The Scientiﬁc World Journal
2. Chronological Age versusPhysiological Age
Ageism, or prejudice based on age alone, may be present
when older patients come for evaluation of a cancer and are
evaluated for their diagnosis and oﬀered treatment recom-
mendations. As one ages, a progressive but largely variable
loss of physiological and cognitive function occurs and is
relevant to the evaluation of an elderly cancer patient [10–
13]. Due to this loss of function, along with increasing com-
orbidities, a more comprehensive assessment of the geriatric
patient may be warranted.
In the general home-dwelling geriatric population, an
aggressive program of in-home comprehensive geriatric
assessments (CGAs) may delay the development of disability
and reduce permanent nursing home stays [14]. Similarly, in
the oncogeriatric population, a CGA may help with clinical
decision making [10–13, 15–17]. The scale is an assessment
of not only an individual’s general and oncologic health,
as typically assessed in general medical and oncologic eval-
uations, respectively, but also includes a comprehensive asse-
ssment of functional status, nutrition, cognition, socioeco-
nomic, and emotional conditions [13, 16] and has been
found, even in a population of patients with good perfor-
mancestatus,toaddmeaningfullytotheassessmentofonco-
geriatric patients [18] who may be candidates for cancer sur-
gery. Extermann and Hurria reviewed studies of CGA in
older adults and concluded that CGA predicted survival,
chemotherapytoxicity,postoperativemorbidity,andmortal-
ity in cancer patients [17]. Although some have called for
the use of CGA for all elderly patients, regardless of age, to
guide oncologic treatment plans [19, 20] ,as u r v e yo fb r e a s t
surgeons revealed that >80% of patients did not undergo
a geriatric assessment routinely; rather, operative risk was
based predominantly on the American Society of Anesthe-
siologists’ (ASA’) grade in 45% of respondents [21]. As the
CGA is often time consuming, abbreviated screening scales
to identify patients who would most beneﬁt from a full CGA
have been proposed as well [22, 23].
The preoperative assessment of cancer in the elderly
(PACE) is another measure that has been used in geriatric
oncologypatients potentiallyundergoingoperation. Itbegan
as a prospective, multi-institutional, international investiga-
tion aimed at deﬁning the perioperative risk of oncogeriatric
surgical candidates [24] and has subsequently been studied
in multi-institutional investigations of oncogeriatric surgical
patients[10,11,25,26].PACEextendsCGAtoincludeSatar-
iano’s index of comorbidities (SICs), mini-mental state in-
ventory(MMS),activitiesofdailyliving(ADL),instrumental
activities of daily living (IADL), geriatric depression scale
(GDS),brieffatigueinventory(BFI),theEasternCooperative
Oncology Group performance status (ECOG-PS), and the
ASA(Table 1),inordertomorespeciﬁcallyaddressoperative
risk faced by oncogeriatric patients. The goal was to measure
short-term outcomes such as length of hospital stay and
30-day morbidity and mortality. PACE was shown to be
eﬀective in the preoperative assessment of elderly patients
who underwent elective oncologic surgery: in a consecutive
series of 460 elderly patients (≥70 years old), multivariate
analysis identiﬁed moderate/severe fatigue, dependence in
IADLs, and impaired PS as the most important independent
predictors of postoperative complications [26]. Similarly,
disability as assessed by dependence in ADLs and IADLs and
impaired PS were associated with an extended hospital stay
[26]. This and several other prospective studies support the
use of formal geriatric assessments to improve outcomes in
oncogeriatric patients (Table 2).
Acute-care admissions are associated with the develop-
ment of age-related complications, such as delirium. In a
population of 551 patients ≥65 yearsold and newly admitted
to facilities following acute-care hospitalization, those who
developed delirium were signiﬁcantly older than those who
did not [27]. In addition, patients with delirium had worse
functional status than those without delirium as indicat-
ed by higher ADL and IADL scores [27]. Following opera-
tions, aging-related complications such as delirium are even
more problematic than those in the nonoperative acute-care
hospital setting and correlate independently with poor func-
tional recovery. For example, in a series of 126 patients ≥65
years old undergoing hip replacement, delirium occurred in
52 (41%) patients and persisted in 20/52 (39%) at hospital
discharge, 15/52 (32%) at 1 month, and 3/52 (6%) at 6
months [28]. Patients ≥80 years old, or with prefracture cog-
nitive impairment, ADL impairment, and comorbidities,
were more likely to develop delirium. However, even after
adjustment for all of these factors, delirium was still associ-
ated with poor functional recovery at 1 month [28].
Several tools are available for preventing age-related
complications such as delirium during the perioperative pe-
riod. For example, given the common association between
polypharmacy and associated adverse drug reactions in the
oncogeriatric population, a formal medicine-review tool
such as STOPP (screening tool of older persons’ potentially
inappropriate prescriptions) should be considered in all eld-
erly patients undergoing cancer operations [29]. Also, regar-
dless of the presence of polypharmacy, a preoperative geri-
atrics consultation has been shown by randomized control-
leddatatopreventdeliriuminpatientsfollowinghipfracture
[30].
Decisions regarding recommendations for cancer treat-
ment in the elderly population will likely continue to be
increasingly common in the upcoming years as the elderly
population increases. Assessment tools such as those includ-
ed in PACE provide an appropriate and useful means of
avoiding ageism by basing recommendations on physiologic
rather than solely on chronologic age. In this paper; there-
fore,theterm“age”willoftenbeusedinaglobalsense,incor-
porating both chronologic age and physiologic age with the
attendant comorbidities prevalent in the elderly population.
3. Cancer Screening
Cancer screening is the testing for an undiagnosed and asy-
mptomatic cancer in individuals at reasonable risk for devel-
oping the cancer. In order to justify the risks of screening,
the beneﬁts of screening must outweigh the risks, which may
be both direct, procedure-related risks and indirect result-
related risks. Direct, procedure-related risks range from mild
anxiety, pain, and discomfort associated with phlebotomyThe Scientiﬁc World Journal 3
Table 1: Preoperative assessment of cancer in the elderly (PACE): a comprehensive assessment of underlying characteristics of elderly cancer
patients prior to elective surgery.
First author Name of test Abbreviation [Ref]
Satariano Satariano’s modiﬁed index of comorbidities SIC [31]
Folstein Mini-mental state MMS [32]
Katz Activities of daily living ADL [33]
Lawton Instrumental activities of daily living IADL [34]
Yesavage Geriatric depression scale GDS [35]
Mendoza Brief fatigue inventory BFI [36]
Oken ECOG performance status PS [37]
ASA American Society of Anesthesiologists’ grade ASA [38, 39]
Table 2: Prospective studies on the eﬀect of geriatric assessment before cancer surgery.
First author, year [ref] N Age (min, mean) Cancer Intervention Results
McCorkle et al., 2000 [40] 375 60, NR Solid
Advance-practice nurses
(APNs) for postsurgical
home care
Improved survival with APNs
Repetto et al., 2002 [18] 363 65, 73 Solid and
hematologic CGA CGA added to PS, even PS is high
Freyer et al., 2005 [41] 83 70, 76 Ovarian
CGA to predict STox;
patient autonomy;
comorbidities; nutritional
status
CGA predicted toxicity and
overall survival
Pope et al. (PACE), 2006 [25] 460 65, 77 Breast, GI, GU PACE PACE associated with
complications
Goodwin et al., 2003 [42] 335 65, ∼72 Breast Nurse case management Improved management
to severe procedure-related morbidity and mortality such as
endoscopic perforations of hollow viscera. Indirect, result-
related risks include both false-positive results that lead to
unnecessary further diagnostic or treatment procedures and
false-negative results that lead to delay in diagnosis. To opti-
mize this risk/beneﬁt ratio, certain characteristics of both the
cancer and the screening test should be present (reviewed
in [43]). An ideal screening test is safe, inexpensive, able to
detectthecanceratanearlystage,andabletodosoaccurately
(with high sensitivity and speciﬁcity). An ideal cancer for
screening is one that, if missed, levies a high cost of mor-
bidity and mortality as well as ﬁnancial cost to society dur-
ing its treatment, one whose incidence and prevalence are
high enough to justify screening, one with a well-character-
ized natural history and biology, and one for which eﬀective
treatment options exist (Table 2). In the very elderly individ-
ual, who is at increasing risk of death due to cardiovascular,
cerebrovascular, and other noncancer diseases, the question
of when—if ever—to stop cancer screening becomes increas-
ingly relevant.
3.1. Breast Cancer Screening. Screening for breast cancer is
commonly accepted for female patients beginning at age 40,
and the American Cancer Society (ACS) recommends con-
tinuing mammographic screening as long as a woman is
in good health [1]. In women aged 40–74, mammography
has been shown in a 2002’s review of randomized control-
led trials (RCTs) for the US Preventive Services Task Force
(USPSTF) to reduce breast cancer mortality rates [44]. There
is a lack of good evidence, however, for similar recommen-
dations in patients older than 74 years. For these patients
>74 years of age, the USPSTF study concluded that there
is insuﬃc i e n td a t at om a k er e c o m m e n d a t i o n si nt h i sa g e
group [45], and some have indeed argued against screening
mammography in women >80 years old, citing concerns that
screening may be more harmful than beneﬁcial [46].
Giventheinsuﬃcientdatainrealpeople,modeledpeople
have been studied in a stochastic model using the Monte-
Carlo simulation, in which the natural history of breast can-
cer is used to evaluate costs, harms, and beneﬁts associated
with screening cessation at various ages [47]. Based on age-
dependent biology and incorporating a cost analysis, it was
found that the beneﬁts of mammography beyond the age of
79 were too low relative to the costs to justify their continued
biennial use [47]. Compared to stopping screening at age 70,
extended screening to age 79 saved only 2.4 days of life per
woman for the entire population but provided an additional
24.9 days of life per woman destined to develop breast cancer
at an incremental cost of $82,063 per life year saved [47].
The authors concluded that extending screening beyond age
79 may be reasonable for women in the top quartile of life
expectancies [47].
Other ways to make the continued use of mammograms
cost eﬀective in this group of very elderly women include
expanding screening intervals or selectively screening only
patients with an increased risk of developing breast cancer4 The Scientiﬁc World Journal
or at decreased risk of natural-cause death in very healthy
individuals. Indeed, there is evidence that physicians and
patients are already making screening decisions based upon
patients expected mortality in this age group: in a series of
5554Medicarebeneﬁciaries,useofscreeningmammography
in older women ≥65 years old was signiﬁcantly associated
with their decreased 4-year risk of mortality rather than with
age alone, suggesting that, when making decisions regarding
screening in elderly women, patients and providers do
already appropriately consider general health,prognosis, and
life expectancy [48].
3.2. Prostate Cancer Screening. S i m i l a rt ob r e a s tc a n c e r
screening, prostate cancer screening is controversial in the
elderlywithconﬂictingdatapublished[49].TheACSrecom-
mends that screening cease once men reach a life expectancy
of <10 years, since such men “are not likely to beneﬁt,”
but appropriately caution that “[o]verall health status, and
not age alone, is important when making decisions about
screening” [50]. Whereas a study of over 2000 elderly men
from the Duke Prostate Cancer Database concluded that it
may be safe to discontinue screening in men 75–80 years
old [51], a recent query of the Center for Prostate Disease
Research database has shown that men >70 years old had a
statistically signiﬁcant higher prediagnosis prostate speciﬁc
antigen increase, higher clinical stage, and higher biopsy
grade, compared with their younger counterparts, raising
concern regarding cessation of screening in this age group
[52]. As with breast cancer recommendations, the soundest
course of action regarding prostate cancer screening deci-
sions is likely to consider patients on a case-by-case basis,
taking into account prognosis and overall health status, as
supportedbybothconsensusstatements[53]andbytheACS
recommendation [50] to consider overall health status as
opposedtoagealonewhenmakingdecisionsaboutscreening
for prostate cancer in the very elderly.
3.3. Colorectal Cancer Screening. Given its accessibility to
screening and its high incidence of cancer, the colon, like the
breast and the prostate, is highly amenable to screening such
that colorectal cancer (CRC) is a largely preventable disease,
the incidence and mortality of which have decreased in
association with increased screening. However, as with pros-
tateandbreastcancer,theremaycomeanagewhenscreening
may no longer provide a favorable risk/beneﬁt ratio. The
USPSTFcurrentlyrecommendsagainstroutinescreeningfor
CRC in the elderly population 76 to 85 years of age, with the
grade C recommended caveat such that, for individual pa-
tients in this group, screening may be considered [54]. A
grade D recommendation is provided by the USPSTF against
screening for CRC in those >85 years old [54]. As evidenced;
however, by the low grades of the recommendations, little
evidence exists to guide decision making, consistent with a
recentsystematicreviewofthescantpublishedevidence[55].
In the absence of convincing evidence, surveyed physi-
cians have appropriately considered a wide range of factors,
includingnotonlyclinicalfactorssuchasage,lifeexpectancy,
comorbidities, and functional status but also psychosocial
factors, such as personality, previous screening behavior,
social support, and the physician-patient relationship [56].
In an eﬀort to improve decision making and with the un-
derstanding that patient preferences matter in such cases of
scant data, Lewis et al. used formative research and cognitive
testing to develop and reﬁne a decision aid designed to pro-
mote individualized decision making regarding CRC screen-
ing [57]. In this uncontrolled trial enrolling 46 patients ≥75
years of age, use of the decision aid was associated with a log-
arithmic increase in the proportion of participants with ade-
quate knowledge enabling them to participate in a meaning-
ful way in decision making (from 4% to 41%), suggesting
that with adequate education elderly patients can and should
be able to participate in the decision to choose the risks of
screening versus the risks of missing an undiagnosed CRC
[57].Giventhatrisksofscreeningmaybegreaterintheelder-
ly than in middle-aged individuals [58, 59], the decision to
proceed with screening in the elderly must be well informed
and made with caution.
Ingeneral,riskofcolorectal(orbreastorprostate)cancer
shouldbeassessedwithacompletehistory(personalorfami-
lial history of cancer, history or prior radiation, etc.) and
a complete annual physical exam, including digital rectal
exam, to assess overall health and estimate life expectancy, all
of which entail minimal to no risk to the geriatric patient.
Screening for patients with a life expectancy of >5y e a r s
should be considered. With colorectal cancer in particular, it
is important to note that many screening tools exist, each
with its own risk proﬁle, including annual fecal occult blood
testing alone, ﬂexible sigmoidoscopy every 5 years with or
without fecal occult blood testing, barium enema every 5
years, or colonoscopy every 10 years.
4.Ageism inDecision-MakingProcess
regardingCancer Surgery in the Elderly?
Once the diagnosis of cancer has been made in an elderly in-
dividual, whether by screening or by investigation of symp-
toms, treatment decisions have been shown, for better or for
worse, to correlate with chronologic age. In a large survey of
primary care providers in France, for instance, in a multi-
variate analysis, chronological age of the patient was highly
associated with the decision not to refer patients with ad-
vanced (not deﬁned) cancer to oncologic specialties (odds
ratio 0.55; 95% conﬁdence interval 0.35–0.86; P = 0.009)
[60].
If elderly patients are referred to an oncologic specialty,
furtherageismmayexisttheretoo:inasurveyof1408French
medical and radiation oncologists to whom breast cancer
patients were referred, signiﬁcant diﬀerences in treatment
choice were observed depending only on patient age [61].
Following the 1990’s National Institutes of Health Consensus
Conference recommendation that patients with stage III
CRC receive adjuvant chemotherapy to increase survival
[62],prospectivedatafrom85,934suchpatientswereentered
into the National Cancer Data Base and studied to determine
whether adjuvant therapy failed to beneﬁt any speciﬁc
sets of patients; although elderly patients derived the same
beneﬁt as younger patients, they were less frequently treated
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Underscoring the importance of the above-discussed
CGA in elderly cancer patients, a study of 161 such patients
who were referred for geriatric consultation, and who under-
went CGA, found that the CGA signiﬁcantly inﬂuenced the
ﬁnal cancer-related treatment decisions in 82% of the elder-
ly cancer patients [64]. Similarly, tools exist within surgical
subspecialties to assist in the risk stratiﬁcation of oncoge-
riatric patients being considered for curative-intent cancer
surgery [65].
5. Studiesof Cancer Surgeryin Elderly Patients
Once the decision has been made to proceed with curative-
intent operation in an elderly patient, do operative outcomes
support the decision to have elderly patients subjected to
invasive procedures? Given that the greatest risks are asso-
ciated with the largest operations [66], review of major tho-
racic and abdominal and operations will prove most useful
to answer this question.
In the thoracic surgical oncology literature, some large
population-based studies, such as that by Owonikoko et al.
analyzing the Surveillance, Epidemiology, and End Results
(SEER) Database, including over 45,000 patients, have sug-
gested that patients >80 years old were less likely to undergo
operationorradiationandhadinferioroutcomeswhencom-
pared with younger patients [67]. However, analysis of more
recent studies focusing on age as an independent risk factor
support the decreasing importance of chronologic age alone
in the preoperative risk evaluation of patients prior to eso-
phageal [68, 69] and pulmonary [70–73]r e s e c t i o n .
Similarly, although large population-based studies in the
pancreatic literature suggest worse short-term outcomes in
older, compared to younger, patients [74, 75], it is likely that
“age” in these population-based studies was simply a surro-
gate for chronic illness. When large series of elderly patients
undergoing major pancreatic and hepatobiliary operations
are analyzed, chronological age turns out not to be a mean-
ingful risk factor, although all agree that physiologic age as
described above is essential to consider [76–80]. When the
contribution of chronologic age was isolated statistically
using logistic regression modeling with pseudo r2 analysis in
oneoftheworld’slargestseriesofpancreaticoduodenectomy,
age alone was found to contribute less than 1% to morbidity
and mortality, whereas chronic obstructive pulmonary dis-
ease and coronary artery disease had a nearly 4-fold and 5-
fold increased impact, respectively, [76].
In addition to physiologic health; however, patient goals
must be taken into account when considering a major pan-
creaticresection,especiallyonenotforknowncancer,butfor
a premalignant lesion such as branch-duct intraductal papil-
lary mucinous neoplasm (BD IPMN), for which consensus
guidelines recommend resection at the 3-cm threshold in
the general population [81, 82]. As with considerations of
colorectal screening discussed above [56], the personal goals
and preferences of the elderly patient are highly relevant
and warrant careful consideration. To address this issue,
Weinberg et al. employed the Markov modeling of the com-
peting goals of maximizing survival and quality of life [83].
The decision to resect or to surveil a BD IPMN depended on
patient age and comorbidities, on the size of the cyst, and
whether the modeled patient placed more valued on qual-
ity or quantity of life: those valuings primarily survival, ir-
respective of quality of life, were found to beneﬁt most from
resection of lesions >2cm, whereas patients valuing quality
of life over longevity derived a greater beneﬁt from a 3-cm
threshold for resection.
Leaving aside the question of diﬀerences in the outcomes
of morbidity and mortality in older versus younger patients,
thereareclearlyotherdiﬀerences.Forexample,diﬀerencesin
histology exist in the elderly: an analysis of elderly lung
cancer patients in the SEER database revealed fewer cases of
adenocarcinoma in older patients: 33% in those <70 years
old compared with 27% in those aged 70 to 79 years and
23% in patients ≥80 years old [67]. Even more relevant to
the surgical treatment of elderly cancer patients is a study of
the National Cancer Data Base (NCBD), including 142,009
N0M0 patients who underwent colectomy for adenocarci-
noma: adequate (≥12 nodes harvested) lymph node counts
obtained in only 41% if patients >78 years old (median 10
nodes) compared to 48% in patients <67 years old (median
11 nodes) (P<0.0001 for the percent of patients with ade-
quate nodal harvests, but NS for the median nodes harvest-
ed). Given that one of the key prognostic indicators of col-
orectal cancer is the number of lymph nodes harvested dur-
ing surgical resection, this study highlights the need for in-
creased use of techniques to increase the harvest in elderly
patients. Increased awareness of such age-related diﬀerences
is mandatory for those providing surgical treatment for the
increasing elderly population of cancer patients.
6.Age-Speciﬁc Mechanismsof
Carcinogenesisand Immunity
Given that physiologic age is so much more appropriate than
chronological age in the evaluation of the oncogeriatric pa-
tient, what is it that makes a physiologically old patient old?
Are these some of the same mechanisms that contribute to
the increased incidence of cancer in the elderly?
6.1. Impaired Stress Response in the Elderly (Impaired Repair).
Thefunctionsofcellschangeprofoundlywithadvancingage.
Among the best-documented changes is the ability of cells
to respond to proliferative and stress-causing agents [84, 85].
Thecellsofayoungpersonrespondoptimallytosuchagents,
mounting an appropriate molecular response that preserves
tissue homeostasis and maintains health. By contrast, the
cells of an elderly individual responding to the same stimuli
mount aberrant molecular responses which can be inade-
quate in magnitude, quality, and/or timing [86]. In turn, this
impairment underlies much of the age-related physiologic
decline, like the loss of muscle mass, immune function,
skin elasticity, and fertility, as well and the increase in age-
associated pathologies like neurodegeneration, cardiovascu-
lar disease, diabetes, and cancer [87–92].
6.2. Increased Senescence (an Anticancer Mechanism) Can Be
Procarcinogenic in the Elderly. A person’s cells frequently
encounter damage from internal and external sources. To6 The Scientiﬁc World Journal
preserve tissue function, mild damage is typically repaired,
whereasseveredamagemaytriggercelldeathviaapoptosisor
necrosis. However, some cellular damage can be oncogenic,
for example, DNA mutations that activate oncogenes or in-
activate tumor suppressor genes (reviewed in [93]). Such
promalignant mutations typically trigger a process named
cellularsenescence,controlledbythep53andRBtumorsup-
pressor proteins, whereby cells cease cell division but remain
metabolically active. In young persons, cellular senescence is
a potent tumor-suppressive mechanism and promotes early-
life survival; in the elderly, however, cellular senescence can
also limit longevity by contributing to aging and to age-
related diseases, including cancer [94]. In this regard, senes-
cent cells can promote cancer by stimulating the so-called
senescence-associated secretory phenotype (SASP), whereby
cells secrete high levels of cytokines and chemokines, trigger-
ing a strong proinﬂammatory response. A proinﬂammatory
state can be pro-oncogenic by, for example, favoring the
proliferation, migration, and invasion of premalignant cells.
However, the picture is more complex, since SASP can
also maintain the senescent phenotype and, thus, prevent
oncogenic progression [95].
6.3. Decreased Immune Function in the Elderly. The immune
system plays a key role not only in the prevention and man-
agement of postoperative complications following cancer
surgery but also in the defense of the body against cancer
development and progression. Cancer immunosurveillance
is the ability of the immune system to prevent tumorigenesis
and the spread of cancer cells by recognizing cancer antigens
and preventing cancer cell proliferation. If the immuno-
surveillance is eﬃcient, cancerous cells are inhibited or eli-
minated, thus, reducing or preventing cancer growth [96].
With advancing age, however, several well-known alterations
impair both the innate immunity (immunosurveillance) and
the adaptive immunity (type and amount of T and B lym-
phocytes, as well as the cytokines they produce) [97]. These
detrimental changes are collectively termed immunosenes-
cence [98, 99]. Although deﬁnitive evidence is needed,
this decline in immune strength is widely considered to
contribute to the higher incidence of cancer among the
elderly.
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